Cargando…

Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network

INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from sponta...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzo, Lucia, Navarria, Andrea, Benfatto, Giuseppe, Longo, Laura, Mansueto, Silvana, Sottosanti, Laura, Pani, Luca, Salomone, Salvatore, Drago, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643364/
https://www.ncbi.nlm.nih.gov/pubmed/28856572
http://dx.doi.org/10.1007/s40261-017-0566-4
_version_ 1783271515608842240
author Gozzo, Lucia
Navarria, Andrea
Benfatto, Giuseppe
Longo, Laura
Mansueto, Silvana
Sottosanti, Laura
Pani, Luca
Salomone, Salvatore
Drago, Filippo
author_facet Gozzo, Lucia
Navarria, Andrea
Benfatto, Giuseppe
Longo, Laura
Mansueto, Silvana
Sottosanti, Laura
Pani, Luca
Salomone, Salvatore
Drago, Filippo
author_sort Gozzo, Lucia
collection PubMed
description INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs). METHODS: Suspected ADRs for ticlopidine, clopidogrel, prasugrel and ticagrelor, reported on the Italian National Pharmacovigilance Network between January 2009 and December 2016, were included in the analysis. All suspected ADRs were classified by frequency, seriousness, outcome, age and system organ class. RESULTS: Clopidogrel showed the highest absolute number of suspected ADRs, followed by ticlopidine. However, these data need to be contextualized in view of the differences in marketing authorization dates, prescription rates and a characterization of the relative seriousness of ADRs per each drug. After the correction for prescription rate, ticagrelor showed the highest reporting trend and ticlopidine the lowest. Most ADRs occurred in the elderly, in particular for ticlopidine. Bleeding represents one of the most reported events (ticlopidine 40%, clopidogrel 26%, prasugrel 42%, ticagrelor 30%) and aspirin was the most frequently associated suspected drug. The majority of ADRs had complete recovery and were non-serious, except for ticlopidine (serious ADRs 53%). Prasugrel showed the highest percentage of ‘life-threatening’ events and ‘death’. CONCLUSIONS: Based on the analysis conducted on spontaneous ADRs reporting system in Italy, the safety profile of antiplatelet drugs seems favourable. However, the overall risk-benefit ratio of these drugs needs to be reassessed taking into account the appropriateness of use in particular populations at risk, such as the elderly. Based on this information, we believe that more attention from clinicians and/or an implementation of regulatory measures could be useful for clinical practice.
format Online
Article
Text
id pubmed-5643364
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-56433642017-10-27 Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network Gozzo, Lucia Navarria, Andrea Benfatto, Giuseppe Longo, Laura Mansueto, Silvana Sottosanti, Laura Pani, Luca Salomone, Salvatore Drago, Filippo Clin Drug Investig Original Research Article INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs). METHODS: Suspected ADRs for ticlopidine, clopidogrel, prasugrel and ticagrelor, reported on the Italian National Pharmacovigilance Network between January 2009 and December 2016, were included in the analysis. All suspected ADRs were classified by frequency, seriousness, outcome, age and system organ class. RESULTS: Clopidogrel showed the highest absolute number of suspected ADRs, followed by ticlopidine. However, these data need to be contextualized in view of the differences in marketing authorization dates, prescription rates and a characterization of the relative seriousness of ADRs per each drug. After the correction for prescription rate, ticagrelor showed the highest reporting trend and ticlopidine the lowest. Most ADRs occurred in the elderly, in particular for ticlopidine. Bleeding represents one of the most reported events (ticlopidine 40%, clopidogrel 26%, prasugrel 42%, ticagrelor 30%) and aspirin was the most frequently associated suspected drug. The majority of ADRs had complete recovery and were non-serious, except for ticlopidine (serious ADRs 53%). Prasugrel showed the highest percentage of ‘life-threatening’ events and ‘death’. CONCLUSIONS: Based on the analysis conducted on spontaneous ADRs reporting system in Italy, the safety profile of antiplatelet drugs seems favourable. However, the overall risk-benefit ratio of these drugs needs to be reassessed taking into account the appropriateness of use in particular populations at risk, such as the elderly. Based on this information, we believe that more attention from clinicians and/or an implementation of regulatory measures could be useful for clinical practice. Springer International Publishing 2017-08-30 2017 /pmc/articles/PMC5643364/ /pubmed/28856572 http://dx.doi.org/10.1007/s40261-017-0566-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Gozzo, Lucia
Navarria, Andrea
Benfatto, Giuseppe
Longo, Laura
Mansueto, Silvana
Sottosanti, Laura
Pani, Luca
Salomone, Salvatore
Drago, Filippo
Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title_full Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title_fullStr Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title_full_unstemmed Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title_short Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
title_sort safety of antiplatelet agents: analysis of ‘real-world’ data from the italian national pharmacovigilance network
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643364/
https://www.ncbi.nlm.nih.gov/pubmed/28856572
http://dx.doi.org/10.1007/s40261-017-0566-4
work_keys_str_mv AT gozzolucia safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT navarriaandrea safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT benfattogiuseppe safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT longolaura safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT mansuetosilvana safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT sottosantilaura safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT paniluca safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT salomonesalvatore safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork
AT dragofilippo safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork